# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Below are summaries of the posters presented: Poster Board 701: "Healthcare Burden of Pulmonary Alveolar Proteinosis" ...
Evercore ISI Group maintains Savara (NASDAQ:SVRA) with a Outperform and lowers the price target from $10 to $7.
HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $6 price target.
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 1...
JMP Securities analyst Jonathan Wolleben reiterates Savara (NASDAQ:SVRA) with a Market Outperform and maintains $8 price tar...
JMP Securities analyst Jonathan Wolleben reiterates Savara (NASDAQ:SVRA) with a Market Outperform and maintains $8 price tar...
JMP Securities analyst Jonathan Wolleben reiterates Savara (NASDAQ:SVRA) with a Market Outperform and maintains $8 price tar...
Savara's Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAPCompany to Host Indu...
HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $6 price target.